Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial-Reference-Cited by-同舟云学术

Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial

Published:2011 Issue:2 Volume:3 Page:16
ISSN:1758-9193
Container-title:Alzheimer's Research & Therapy
language:en
Short-container-title:Alzheimers Res Ther

Author:

Piette François,Belmin Joël,Vincent Hélène,Schmidt Nicolas,Pariel Sylvie,Verny Marc,Marquis Caroline,Mely Jean,Hugonot-Diener Laurence,Kinet Jean-Pierre,Dubreuil Patrice,Moussy Alain,Hermine Olivier

Publisher

Springer Science and Business Media LLC

Subject

Cognitive Neuroscience,Neurology (clinical),Neurology

Reference23 articles.

1. Oligomers of β-amyloid are sequestered into and seed new plaques in the brains of an AD mouse model

2. Correlation Between Elevated Levels of Amyloid β-Peptide in the Brain and Cognitive Decline

3. Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy

4. Systemic inflammation and disease progression in Alzheimer disease

5. The role of inflammation in Alzheimer's disease

Cited by 138 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent updates on immunotherapy in neurodegenerative diseases;Brain Research;2024-12

2. Evolving significance of kinase inhibitors in the management of Alzheimer's disease;European Journal of Pharmacology;2024-09

3. Tyrosine kinases: multifaceted receptors at the intersection of several neurodegenerative disease-associated processes;Frontiers in Dementia;2024-08-16

4. Current Therapeutic Options and Repurposed Drugs for Neurodegeneration;Advances in Diagnostics and Immunotherapeutics for Neurodegenerative Diseases;2024-07-28

5. Fyn Kinase in Alzheimer’s Disease: Unraveling Molecular Mechanisms and Therapeutic Implications;Molecular Neurobiology;2024-06-18